Director/PDMR Shareholding

RNS Number : 7223Z
Oxford Biomedica PLC
25 May 2021
 

 

 

 

PDMR Dealing

 

Oxford, UK - 25 May 2021:   Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed on 24 May 2021, that Nicholas Page, Chief Operations Officer of the Group, exercised 4,119 DBP (2019) options at nil cost, and sold all the resulting ordinary shares at 1128p per share. Following this transaction Nicholas Page continues to hold 89,436 options over ordinary shares.

 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Nicholas Page

2.

Reason for the notification

a)

Position/status

Chief Operations Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford BioMedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Options over ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Exercise of options

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

 

Price(s)

Volume(s)

Nil

4,119

 

 

e)

Aggregated information

Aggregate volume

 

Price

 

Aggregated total

 

 

4,119

 

 

Nil

 

Nil

f)

Date of the transaction

2021-05-21

g)

Place of the transaction

Outside a trading venue

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Nicholas Page

2.

Reason for the notification

a)

Position/status

Chief Operations Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford BioMedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Disposal

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

 

Price(s)

Volume(s)

£11.28

 4,119

 

 

e)

Aggregated information

Aggregate volume

 

Price

 

Aggregated total

 

 

4,119

 

 

£11.28

 

£46,462.32

f)

Date of the transaction

2021-05-21

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

-Ends-

 

For further information, please contact:

 

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGIGDUGDDDGBU
UK 100

Latest directors dealings